AUROBINDO
Committed to healthier life!
www.AurobindoUSA.com

July 17, 2017

Press Release

Dear Valued Customer,

Aurobindo Receives FDA Approval for the line of OC tablets Aurovela™

East Windsor, N.J. - Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for Aurovela™ line of OC tablets. The Division of Bioequivalence has determined Aurobindo Pharma Limited's Aurovela™ to be bioequivalent and, therefore, therapeutically equivalent to Loestrin® line of oral contraceptive products. Please see table below for each of the following product approvals.

Product Name	Strength	Brand Equivalent
Aurovela™ Fe 1.5/30 Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets USP	1.5 mg/30 mcg and 75 mg	Loestrin Fe 1.5/30
Aurovela™ 24 Fe Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets USP	1 mg/20 mcg and 75 mg	Loestrin 24 Fe
Aurovela™ Fe 1/20 Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets USP	1 mg/20 mcg and 75 mg	Loestrin Fe 1/20
Aurovela™ 1/20 Norethindrone Acetate and Ethinyl Estradiol Tablets USP	1 mg/20 mcg	Loestrin 21 1/20
Aurovela™ Norethindrone Acetate and Ethinyl Estradiol Tablets USP	1.5 mg/30 mcg	Loestrin 21 1.5/30

Aurovela™ line of tablets are oral contraceptives indicated for the prevention of pregnancy in women.

The combined products have an estimated market size of $315.9M for the twelve months ending May 2017 according to IMS*.

Aurovela™ line of OC tablets represents the latest addition to Aurobindo's broad line of generic pharmaceuticals. Aurobindo's product portfolio consists of 291 final approvals, including 36 tentative approvals. There are 102 additional products on file with U.S. FDA.

* IMS National Sales Perspectives: Retail and Non-Retail MAT June 2017

Aurobindo Pharma USA, Inc. • 279 Princeton Hightstown Road • East Windsor, NJ 08520-1401
{phone}866.850.2876 • {fax}732.355.9449